- Conditions
- Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
- Procedure · Drug · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 435
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Interventions
- melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
- Drug · Procedure
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 12
- States / cities
- Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
- Conditions
- Cancer of Liver
- Interventions
- Capecitabine (Xeloda)
- Drug
- Lead sponsor
- James A. Haley Veterans Administration Hospital
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
- Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Interventions
- floxuridine, leucovorin calcium, melphalan
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer of the Bile Duct
- Interventions
- Regorafenib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Chapel Hill, North Carolina • Richmond, Virginia
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Balstilimab (BAL), Botensilimab (BOT), agenT-797
- Drug
- Lead sponsor
- Darren Sigal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- falimarev, inalimarev, sargramostim, therapeutic autologous dendritic cells
- Biological
- Lead sponsor
- Michael Morse, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Durham, North Carolina + 3 more
- Conditions
- Colorectal Cancer; Lung Cancer
- Interventions
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Drug
- Lead sponsor
- Teclison Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver
- Interventions
- DENEB
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Monrovia, California • San Diego, California
- Conditions
- Liver Cancer
- Interventions
- Intratumoral Dendritic Cell Immunotherapy, autologous dendritic cells
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric Cancer Stage, Gastric Neoplasm, Gastric Lesion, Gastric Cancer in Situ, Gastric Cancer Stage IV, Gastric Cancer Stage IIIB, Gastric Cancer Stage III, Gastric Cancer Stage IB, Gastric Cancer Stage IA, Gastric Cancer, Stage 0, Gastric Cancer Stage IIIA, Gastric Cancer Stage II, Gastric Cancer TNM Staging, Gastric Cancer Metastatic to Lung, Gastric Cancer Metastatic to Liver, Gastric Cancer Stage I, Gastric Cancer TNM Staging Primary Tumor (T) T2B
- Interventions
- DESTINEX
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 809 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Melanoma, Liver Metastases
- Interventions
- Nivolumab and Relatlimab, Melphalan
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care, Communication, Advance Care Planning, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, End Stage Liver Disease, Kidney Failure, Chronic
- Interventions
- Communication Feedback Form for Patients with Serious Illness
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 817 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Renton, Washington • Seattle, Washington
- Conditions
- Liver Cancer, Metastatic Cancer
- Interventions
- Yttrium Y 90 glass microspheres
- Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Liver Cancer
- Interventions
- CT guided percutaneous ablation
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
- Interventions
- Stereotactic body radiosurgery, Stereotactic Body Radiotherapy
- Radiation
- Lead sponsor
- Mercy Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Liver Cancer
- Interventions
- bevacizumab, sorafenib tosylate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 177
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 113 more
- Conditions
- Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
- Interventions
- Ad-P53, Xeloda, Keytruda, Opdivo
- Drug
- Lead sponsor
- MultiVir, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma
- Interventions
- Laparotomy
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer
- Interventions
- aminocamptothecin colloidal dispersion
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- cetuximab, fluorouracil, leucovorin calcium, oxaliplatin
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 162
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 103 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- selumetinib, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 3 more
- Conditions
- Carcinoma, Hepatocellular, Neoplasm Metastasis
- Interventions
- yttrium Y 90 microspheres (Therasphere®)
- Device
- Lead sponsor
- Leo W. Jenkins Cancer Center
- Other
- Eligibility
- 19 Years and older
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina